KR20080019720A - 치료 펩티드 및 백신 - Google Patents

치료 펩티드 및 백신 Download PDF

Info

Publication number
KR20080019720A
KR20080019720A KR1020087001808A KR20087001808A KR20080019720A KR 20080019720 A KR20080019720 A KR 20080019720A KR 1020087001808 A KR1020087001808 A KR 1020087001808A KR 20087001808 A KR20087001808 A KR 20087001808A KR 20080019720 A KR20080019720 A KR 20080019720A
Authority
KR
South Korea
Prior art keywords
peptide
composition
group
hiv
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087001808A
Other languages
English (en)
Korean (ko)
Inventor
캔디스 퍼트
마이클 러프
Original Assignee
래피드 파마슈티컬즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 래피드 파마슈티컬즈 인코포레이티드 filed Critical 래피드 파마슈티컬즈 인코포레이티드
Publication of KR20080019720A publication Critical patent/KR20080019720A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
KR1020087001808A 2005-06-23 2006-06-23 치료 펩티드 및 백신 Ceased KR20080019720A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US69308805P 2005-06-23 2005-06-23
US69308905P 2005-06-23 2005-06-23
US69308705P 2005-06-23 2005-06-23
US60/693,088 2005-06-23
US60/693,089 2005-06-23
US60/693,087 2005-06-23

Publications (1)

Publication Number Publication Date
KR20080019720A true KR20080019720A (ko) 2008-03-04

Family

ID=37571305

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087001808A Ceased KR20080019720A (ko) 2005-06-23 2006-06-23 치료 펩티드 및 백신

Country Status (9)

Country Link
US (3) US7700115B2 (https=)
EP (1) EP1893233A4 (https=)
JP (1) JP2008546803A (https=)
KR (1) KR20080019720A (https=)
AU (1) AU2006261133B2 (https=)
BR (1) BRPI0611927A2 (https=)
CA (1) CA2624957A1 (https=)
MX (1) MX2007016573A (https=)
WO (1) WO2006138745A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006261133B2 (en) 2005-06-23 2012-04-05 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines
US8178497B2 (en) 2007-11-14 2012-05-15 Rapid Pharmaceuticals Ag Method of treating HIV in drug resistant non plasma viral reservoirs with monomeric DAPTA
US10130674B2 (en) * 2010-02-09 2018-11-20 Creative Bio-Peptides Modified peptide that reduces pain in peripheral neuropathy
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
US20140092376A1 (en) * 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
US20140322251A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions
US20180344798A1 (en) * 2017-05-31 2018-12-06 Creative Bio-Peptides Inc. Topically active peptides for treating cosmetic and dermatological conditions
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
US20210244788A1 (en) * 2020-02-06 2021-08-12 Creative Bio-Peptides Inc. Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002775A1 (en) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Synthetic peptides and use for diagnosis and vaccination for aids and arc
WO1987007614A1 (en) * 1986-06-03 1987-12-17 Pert Candace B Small peptides which inhibit binding to t-4 receptors
JP2680011B2 (ja) * 1986-06-03 1997-11-19 アメリカ合衆国 Ｔ−４レセプターへの結合を阻害し免疫原として作用する小ペプチド類
US5276016A (en) * 1986-06-03 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Small peptides which inhibit binding to T-4 receptors and act as immunogens
US6242564B1 (en) 1986-06-03 2001-06-05 Candace B. Pert Treatment of tropical spastic paresis with peptide T
US5063206A (en) 1988-12-16 1991-11-05 The United States Of Americas As Represented By The Department Of Health And Human Services Compositions having use as treatment of neuropsychiatric deficits
US5739109A (en) 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
DK64592D0 (da) 1992-05-14 1992-05-14 Carlbiotech Ltd As Peptider til terapeutisk behandling
US6011014A (en) 1992-03-27 2000-01-04 Advanced Immunit, Inc. Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
US5534495A (en) 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US20040126811A1 (en) * 2002-02-21 2004-07-01 Thomas Boren Helicobacter pylori sialic acid binding adhesin, saba and saba-gene
US7390788B2 (en) 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
AU2006261133B2 (en) 2005-06-23 2012-04-05 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines

Also Published As

Publication number Publication date
US20100184705A1 (en) 2010-07-22
EP1893233A2 (en) 2008-03-05
JP2008546803A (ja) 2008-12-25
EP1893233A4 (en) 2010-03-31
CA2624957A1 (en) 2006-12-28
US10973906B2 (en) 2021-04-13
AU2006261133A1 (en) 2006-12-28
AU2006261133B2 (en) 2012-04-05
BRPI0611927A2 (pt) 2011-08-16
US10071153B2 (en) 2018-09-11
MX2007016573A (es) 2008-10-17
US7700115B2 (en) 2010-04-20
US20060292167A1 (en) 2006-12-28
WO2006138745A2 (en) 2006-12-28
US20190000964A1 (en) 2019-01-03
WO2006138745A3 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
US10973906B2 (en) Therapeutic peptides and vaccines
Koch et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition
Naidu et al. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac
Root et al. HIV-1 gp41 as a target for viral entry inhibition
Dowbenko et al. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies
US20100247618A1 (en) Novel synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
Xiang et al. A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer
US20030044411A1 (en) Methods for inhibiting HIV-1 infection
Srivastava et al. Role of neutralizing antibodies in protective immunity against HIV
US20020146415A1 (en) Methods for inhibiting HIV-1 infection
Yuan et al. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor
JP2004522401A (ja) ワクチンおよび治療薬としてのｃｄ４非依存性のｈｉｖエンベロープタンパク質
US20240285790A1 (en) Antibody-cd4 conjugates and methods of using the same
Lagenaur et al. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates
CA2305341C (en) Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain
Khurana et al. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity
WO1998000535A2 (en) Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
AU731975B2 (en) GP120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting HIV infection
Albright et al. Interactions between HIV-1 gp120, chemokines, and cultured adult microglial cells
WO1998015569A9 (en) Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection
CN101242854A (zh) 治疗肽及疫苗
Melikyan et al. The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment
Kim et al. Enhancing HIV-1 neutralization by increasing the local concentration of membrane-proximal external region-directed broadly neutralizing antibodies
Burke et al. Broadening our view of protective antibody responses against HIV
Jekle et al. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20080827

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100903

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120718

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130424

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120718

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I